Molecular Therapy — Nucleic Acids · 2020 · 11 citations · 13 references
Life SciencesNeuroscienceNeurosurgeryClinical NeuroscienceNeurogeneticsTranscriptomicsCerebrospinal Fluid BiomarkersCerebrovascular DiseaseNoncoding Rna TranscriptomicsStrokeSubarachnoid HemorrhageCerebral Vasospasm MonitoringCerebral Vasospasm PreventionLong Noncoding Rna ProfilingNeurological Outcome PredictionSubarachnoid Hemorrhage PrognosticationSubarachnoid SpaceVasospasm Detection
Subarachnoid hemorrhage (SAH) patients' surgery is performed to prevent extravasation of blood into the subarachnoid space. Cerebral vasospasm (CVS; narrowing of cerebral arteries) occurs following SAH and represents a major cause of associated mortality and morbidity. To improve postsurgery care of SAH patients and their prognosis, the ability to predict CVS onset is critical. We report a long noncoding RNA (lncRNA) signature to distinguish SAH patients with CVS from SAH patients without CVS. Cerebrospinal fluid (CSF) was obtained from SAH patients without CVS (n = 10) and SAH patients with CVS (n = 10). lncRNAs ZFAS1 and MALAT1 were significantly upregulated (p < 0.05), whereas lncRNAs LINC00261 and LINC01619 were significantly downregulated in SAH patients with CVS (p < 0.05) compared to SAH patients without CVS. We applied this lncRNA signature to retrospectively predict CVS in SAH patients (n = 38 for SAH patients without CVS, and n = 27 for SAH patients with CVS). The 4-lncRNA signature was found to be predictive in >40% of samples and the 2-lncRNA comprising MALAT1 and LINC01619 accurately predicted CVS in ∼90% cases. These results are initial steps toward personalized management of SAH patients in clinics and provide novel CSF biomarkers that can substantially improve the clinical management of SAH patients.
13
Controversies and evolving new mechanisms in subarachnoid hemorrhage
Sheng Chen, Hua Feng, Prativa Sherchan et al. · Progress in Neurobiology · 2013 · 356 citations